Loading
Evopoint Biosciences
Evopoint Biosciences is a China-based biotechnology company running 6 late-stage cancer trials of XNW29016, XNW5004 and XNW28012 in peripheral T-cell lymphomas, follicular lymphoma and prostate cancer.
Also called: Evopoint Biosciences Inc.
Overview
Evopoint Biosciences, based in Suzhou, China, is a biotechnology company. An innovation-focused pharmaceutical company (registered in Chinese as Suzhou Xinnuowei Pharmaceutical Technology Co., Ltd., 苏州信诺维医药科技股份有限公司) developing small-molecule and antibody drugs for precision oncology and multi-drug resistant bacterial infections, using in-house small molecule, complex antibody (eMAB) and targeted protein degradation (eGLUE) platforms. On ClinicalTrials.gov it is the lead sponsor of 6 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing XNW29016, XNW5004 and XNW28012 in peripheral T-cell lymphomas, follicular lymphoma, prostate cancer, hodgkin lymphoma and pancreatic ductal adenocarcinoma. The largest, NCT06799637 (Study of XNW28012 in Subjects With Advanced Solid Tumours Who Failed Standard Treatments), plans to enrol 350 participants. In May 2025 Evopoint licensed XNW27011, a clinical-stage antibody-drug conjugate against CLDN18.2 being tested in gastric, gastro-oesophageal junction and pancreatic cancers, to Astellas for development outside mainland China, Hong Kong, Macau and Taiwan, for USD 130 million upfront, up to USD 70 million in near-term payments and up to USD 1.34 billion in milestones. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Suzhou, CN
Scorecard
All companies#282of 1520 companies, score 16
- phase 1/2 +2
- targets +4
- modalities +4
- registry trials +6
0 approved, 0 in phase 3, 2 earlier, 2 targets, 10 registry studies. Formula on the scorecards page.
Type
Website
Products
2Phase 2small molecule (structure undisclosed or not yet in PubChem)
XNW5004 is an experimental small-molecule drug from Evopoint Biosciences in phase 2 trials for follicular lymphoma and prostate cancer, aimed at EZH2.
Phase 2ADC
XNW27011 is an experimental antibody-drug conjugate from Astellas Pharma Global Development in phase 2 trials for pancreatic ductal adenocarcinoma, non-small-cell lung cancer and ovarian cancer, aimed at Claudin 18.2.
Notes
- Freshened 29 October 2026 from the company's Chinese newsroom (Astellas licence, 30 May 2025). The earlier summary gave a garbled Chinese name; it now uses the registered name printed on the company site. No acquisition, listing or renaming found.
Connected
18Similar pages
- TrialXNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
Shares XNW27011, Astellas, Ovarian cancer.
- TrialA Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Shares Astellas, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma.
- CollectionLymphoma Research Foundation (LRF)
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Follicular lymphoma, Hodgkin lymphoma.
- CompanyHaihe Biopharma
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Follicular lymphoma, Hodgkin lymphoma, Ovarian cancer.
- InstitutionLymphoma Action
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Follicular lymphoma, Hodgkin lymphoma.
- InstitutionAnthony Nolan
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Follicular lymphoma, Hodgkin lymphoma.
- InstitutionBlood Cancer UK
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Follicular lymphoma, Hodgkin lymphoma.
- TermCentral venous access (port, PICC line)
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Follicular lymphoma, Hodgkin lymphoma, Pancreatic ductal adenocarcinoma.
cancers
drugs
companies
trials
A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell LymphomaA Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard TreatmentClinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell LymphomaClinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular LymphomaStudy of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard TreatmentsStudy of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic TherapyStudy of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
evopointbio.com · 2
ClinicalTrials.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/